Notes from the Field: Tuberculosis Outbreak Linked to a Contaminated Bone Graft Product Used in Spinal Surgery — Delaware, March–June 2021
Weekly / September 10, 2021 / 70(36);1261–1263
Ruoran Li, ScD1,2,*; W. Wyatt Wilson, MD1,2,*; Noah G. Schwartz, MD1,3; Alfonso C. Hernandez-Romieu, MD1,2; Janet Glowicz, PhD2; Emily Hanlin, MPH4; Malikah Taylor, MPH4; Heather Pelkey5; Carol A. Briody5; Lija Gireesh; DNP5; Mark Eskander, MD5; Kenneth Lingenfelter, DO5; Sandy P. Althomsons, MA3; Rebekah J. Stewart, MSN3; Rebecca Free, MD2; Pallavi Annambhotla, DrPH2; Sridhar V. Basavaraju, MD2; Jonathan M. Wortham, MD3; Sapna Bamrah Morris, MD3; Isaac Benowitz, MD2; Maryam B. Haddad, PhD3; Rick Hong, MD4; Marci Drees, MD5 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
On May 25, 2021, a Delaware acute care hospital notified the Delaware Division of Public Health (DPH) of seven patients who developed tuberculosis after spinal surgery during March–April 2021. Hospital staff members identified a single common exposure: implantation of bone allograft material (product A) from a single product lot. DPH notified CDC, requested a field investigation, and issued a nationwide call for cases. In collaboration with the Food and Drug Administration, a CDC team was deployed to Delaware on June 2 to investigate the epidemiology of cases and opportunities for transmission and to provide prevention and treatment recommendations. On the same day, another state health department notified CDC about a person who developed tuberculosis after surgery involving the same product A lot, and the manufacturer issued a voluntary nationwide recall (1).
Investigators abstracted clinical, laboratory, and imaging data from medical records and interviewed patients. They also assessed potential exposures to Mycobacterium tuberculosis related to product A storage, handling, and use during surgery; reprocessing of surgical instruments; and patient care. This investigation was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.†
Twenty-three patients at the hospital underwent surgery that involved the recalled product lot. The median patient age was 66 years (range = 37–80 years). No patient had an immunocompromising condition.§ One patient had a history of latent tuberculosis infection and completed treatment in 2003. Nineteen (83%) patients reported new symptoms beginning 2–66 days (median = 19 days) after product implantation (Figure). Fifteen (65%) patients reported constitutional signs and symptoms, including fever, chills, night sweats, weight loss, fatigue, and loss of appetite; 16 (70%) had redness, pain, or drainage at the surgical site; four (17%) experienced neurologic symptoms, including paresthesia and dysphagia; and seven (30%) experienced pulmonary symptoms, including cough and shortness of breath. Four (17%) patients were asymptomatic. Sixteen (70%) required hospital readmission 23–84 days after product implantation (median = 52 days). Twelve (52%) underwent additional surgical procedures to manage complications of infection. One patient died at home 3 weeks after product implantation, which was 2 months before the product recall.
As of June 25, 19 (83%) of the 23 patients had laboratory or imaging evidence of tuberculosis in the spine or chest. Among 19 patients who had received microbiologic testing of a vertebral, paraspinal soft tissue, or sputum specimen, 15 (79%) had a positive acid-fast bacilli smear, M. tuberculosis nucleic acid amplification test, or culture. Among 21 patients who had received spinal imaging, 19 (90%) had findings consistent with infection, including abscesses (17, 81%) and osteomyelitis or discitis (eight, 38%). Among 21 patients with sputum testing or chest imaging, six (28%) demonstrated evidence of pulmonary tuberculosis, suggesting bloodborne dissemination of M. tuberculosis. Isolates cultured from specimens from three patient specimens were susceptible to all first-line medications and shared a genotype not previously identified in the United States; drug-susceptibility testing and genotyping of subsequent isolates were pending. All 22 living patients began standard four-drug treatment for drug-susceptible tuberculosis 41–91 days after product implantation (median = 69 days).
Product A was shipped frozen and was opened inside the operating room. Health care personnel could have been exposed to M. tuberculosis during product A implantation and subsequent procedures involving suctioning, drilling, wound irrigation, and decontamination of cannulated instruments. In addition, health care personnel and patients could have been exposed to M. tuberculosis from patients who had received implantations with product A and subsequently developed draining tuberculous lesions or pulmonary tuberculosis (2–4). As of June 24, the hospital had identified 152 health care personnel and seven patients who were exposed to recipients of product A who had tuberculous abscesses or pulmonary tuberculosis; investigations are ongoing to identify additional exposures.
This investigation found high attack rates of spinal and disseminated tuberculosis after surgical implantation of product A and multiple opportunities for M. tuberculosis exposure related to surgery and patient care. On June 4, CDC recommended that all patients nationwide who had undergone surgery involving the affected product A lot be immediately assessed and begin the four-drug treatment for tuberculosis disease, even if they were asymptomatic. On June 8, CDC recommended evaluation of contacts in health care settings, including risk assessment, symptom screening, and an interferon-gamma release assay or tuberculin skin test (3,4).
M. tuberculosis transmission via bone graft was last described in 1953 (5). The hospital’s rapid detection of this unusual cluster triggered a multistate investigation resulting in sequestration of all unused units of the contaminated product, identification of all patients who underwent surgical procedures with the contaminated product lot, and initiation of tuberculosis treatment by all living patients. Public health authorities and health care facilities should continue efforts to identify and evaluate all exposed contacts and identify opportunities to prevent M. tuberculosis exposures from contaminated tissues or other products.
Tuberculosis clinic staff members, Floyd I. Hudson and James W. Williams State Service Centers, Delaware Department of Health and Social Services; Rebecca Savage, Delaware Public Health Laboratory, Delaware Department of Health and Social Services; Cynthia Flynn, Julia Moeller, Mary Stirparo, Tabe Mase, ChristianaCare; Leeanna Allen, Bruce Bradley, Angela Starks, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; Bonnie Herring, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Scott Brubaker, Division of Human Tissues, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration.
Corresponding author: Noah G. Schwartz, firstname.lastname@example.org.
1Epidemic Intelligence Service, CDC; 2Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 4Division of Public Health, Delaware Department of Health and Social Services; 5ChristianaCare, Wilmington, Delaware.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
* These authors contributed equally to this report.
† 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
§ Eight patients had diabetes mellitus and two patients had chronic kidney disease, stage 2–3.
- Food and Drug Administration. Urgent voluntary notification: FiberCel Fiber Viable Bone Matrix (“FiberCel”)—lot number: NMDS210011. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/vaccines-blood-biologics/recalls-biologics/urgent-voluntary-notification-fibercel-fiber-viable-bone-matrix-fibercel-lot-number-nmds210011external icon
- Hutton MD, Stead WW, Cauthen GM, Bloch AB, Ewing WM. Nosocomial transmission of tuberculosis associated with a draining abscess. J Infect Dis 1990;161:286–95 . https://doi.org/10.1093/infdis/161.2.286external icon PMID:2105362external icon
- Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdfpdf icon
- National Tuberculosis Controllers Association. CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54(No. RR-15).
- James JI. Tuberculosis transmitted by banked bone. J Bone Joint Surg Br 1953;35-B:578. https://doi.org/10.1302/0301-620X.35B4.578external icon PMID:13108919external icon
FIGURE. Time line of product implantation, symptom onset,* hospital readmission,† and start of tuberculosis treatment§ in patients exposed to product A¶ (N = 23) — Delaware, March–June 2021
* Excludes one patient with insidious onset of weight loss.
† One patient was readmitted 4 days after product implantation with a surgical site infection caused by nonmycobacterial species; this readmission was excluded from the figure. The patient subsequently developed worsening lumbar back pain and was readmitted with a tuberculous abscess; this subsequent symptom onset and readmission were included in the figure.
§ All 22 living patients have started tuberculosis treatment. One patient died 3 weeks after product implantation, before the tuberculosis outbreak was recognized.
¶ Numbers of patients in each category are as follows: product A implantation = 23 patients; symptom onset = 18; readmission = 16; start of tuberculosis treatment = 22.
Suggested citation for this article: Li R, Wilson WW, Schwartz NG, et al. Notes from the Field: Tuberculosis Outbreak Linked to a Contaminated Bone Graft Product Used in Spinal Surgery — Delaware, March–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1261–1263. DOI: http://dx.doi.org/10.15585/mmwr.mm7036a4external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.